Controversies in the management of neuromyelitis optica spectrum disorder

References

• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535–544.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One. 2013;8:e79083.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1–16.
   PubMed Web of Science ®Google Scholar
• Borisow N, Mori M, Kuwabara S, et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018;23(9):888.
   Google Scholar
• Kim HJ, Friedemann P, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165–1173.
   PubMed Web of Science ®Google Scholar
• Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;7:276–283.
   Google Scholar
• Sato DK, Callegaro DL, Peixot MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–481.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Nagelhus EA, Amiry-Moghaddam M, et al. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997;17:171–180.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classi?ed as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol. 2012;3:58–73.
   Google Scholar
• Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain J Neurol. 1999;122:2047–2056.
   Google Scholar
• Xiao BG, Linington C, Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal ?uid from patients with multiple sclerosis and controls. J Neuroimmunol. 1991;31:91–96.
   PubMed Web of Science ®Google Scholar
• Haase CG, Schmidt S. Detection of brain-speci?c autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic’s neuromyelitis optica. Neurosci Lett. 2001;307:131–133.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroin?amm. 2014;1:e40.
   PubMedGoogle Scholar
• Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019;32:385–394.
   PubMed Web of Science ®Google Scholar
• Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroin?amm. 2015;2:e134.
   PubMed Web of Science ®Google Scholar
• Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, et al. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci. 2016;17:273.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Greenberg BM, et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69:1176–1180.
   PubMedGoogle Scholar
• Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22:185–192.
   PubMed Web of Science ®Google Scholar
• Song W, Qu Y, Huang X. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol. 2019. DOI:10.1007/s10792-019-01090-z
   Google Scholar
• Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014;24(1):e5.
   Google Scholar
• Mealy MA, Shin K, John G, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6:413–418.
   PubMedGoogle Scholar
• Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses ClinicalTrials.gov. cited 2019 May 2. Available online at: https://clinicaltrials.gov/ct2/show/NCT02276963.
   Google Scholar
• Biswas, Mukherjee A. Therapy of NMO spectrum disorders. Ann Indian Acad Neurol. 2015;28:S16–23.
   Google Scholar
• Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019;31:250–255.
   PubMed Web of Science ®Google Scholar
• Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019;6:19–36.
   Google Scholar
• Lin J, Xue B, Li X, et al. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. Int J Neurosci. 2017;127:735–744.
   PubMed Web of Science ®Google Scholar
• Olivieri G, Nociti V, Iorio R, et al. Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. Neurol Sci. 2015;36:2301–2302.
   PubMed Web of Science ®Google Scholar
• Bruscolini A, Sacchetti M, La Cava M, et al. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev. 2018;17:195–200.
   PubMed Web of Science ®Google Scholar
• Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17:1225–1230.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Huh S-Y, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117.
   PubMed Web of Science ®Google Scholar
• Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264:2003–2009.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324–330.
   PubMed Web of Science ®Google Scholar
• Jeong LH, Park B, Kim S-H, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22:329–339.
   PubMed Web of Science ®Google Scholar
• Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015;351(1–2):31–35.
   PubMed Web of Science ®Google Scholar
• Stellmann JP, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: e?cacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88:639–647.
   PubMed Web of Science ®Google Scholar
• Kim SH, Hyun JW, Joung A, et al. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. Mult Scler. 2017;23:1902–1908.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68:412–420.
   Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310–1315.
   PubMed Web of Science ®Google Scholar
• Yang C-S, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81:710–713.
   PubMed Web of Science ®Google Scholar
• Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24:219–226.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang Y, Shi Z, et al. The Efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol. 2016;39:81–87.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang CJ, Wang BJ, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192–197.
   PubMed Web of Science ®Google Scholar
• Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4- IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23:1377–1384.
   PubMed Web of Science ®Google Scholar
• Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–1133.
   PubMedGoogle Scholar
• Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–562.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. May 2019. doi: 10.1056/NEJMoa1900866.
   Web of Science ®Google Scholar
• An open label extension trial of eculizumab in relapsing NMO patients - full text view - Clinicaltrials.gov. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT02003144
   Google Scholar
• Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT02073279.
   Google Scholar
• Efficacy and safety study as add-on therapy of SA237 to treat NMO and NMOSD - full text view - ClinicalTrials.gov. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT02028884.
   Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. AAN Abstract S43.008: efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: A phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD). [cited 2019 Aug 8]. Available from: https://n.neurology.org/content/92/15_Supplement/S43.008.(S43.008)
   Google Scholar
• A double-masked, placebo-controlled study with open label period to evaluate MEDI-551 in neuromyelitis optica and neuromyelitis optica spectrum disorders. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT02200770
   Google Scholar
• Cree B, Bennett J, Kim HJ, et al. AAN Abstract Plen 02.001: A double-masked, placebo-controlled study with open-label period to evaluate the efficacy and safety of inebilizumab in adult subjects with neuromyelitis optica spectrum disorders–top line efficacy. [cited 2019 Aug 8]. Available from: https://n.neurology.org/content/92/15_Supplement/Plen02.001.
   Google Scholar
• Kasama T, Isozaki R, Takahashi R, et al. Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis. Inter Immunopharmacol. 2016;35:301–306.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70:390–393.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter A, Schroder K, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70:394–397.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756–763.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302–1306.
   PubMed Web of Science ®Google Scholar
• A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD ClinicalTrials.gov. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT03062579.
   Google Scholar
• Tocilizumab vs azathioprine in neuromyelitis optica spectrum disorders - full text view - ClinicalTrials.gov. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT03350633.
   Google Scholar
• Verkman AS, Ratelade J, Rossi A, et al. Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sinica. 2011;32:702–710.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71:314–322.
   PubMed Web of Science ®Google Scholar
• Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Int Med. 2010;49:2423–2432.
   PubMed Web of Science ®Google Scholar
• Herges K, De Jong BA, Kolkowitz I, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglia glycoprotein. Mult Scler. 2012;18:398–408.
   PubMed Web of Science ®Google Scholar
• Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71:323–333.
   PubMed Web of Science ®Google Scholar
• Katz Sand I, Fabian MT, Telford R, et al. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018;5:e441.
   PubMed Web of Science ®Google Scholar
• Zhang C, Tian DC, Yang CS, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74:1010–1012.
   PubMed Web of Science ®Google Scholar
• Fu Y, Yan Y, Qi Y, et al. Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: a pilot, 2-year observational study. CNS Neurosci Ther. 2016;22:677–685.
   PubMed Web of Science ®Google Scholar
• Hematopoietic stem cell transplant in Devic’s Disease. cited 2019 May 2. Available from: https://clinicaltrials.gov/ct2/show/NCT00787722.
   Google Scholar
• Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016;30:157–167.
   PubMed Web of Science ®Google Scholar
• Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20. cited 2019 May 2 Available from: https://clinicaltrials.gov/ct2/show/NCT03605238.
   Google Scholar
• Bar-Or A, Steinman L, Behne JM, et al. Restoring immune tolerance in neuromyelitis optica: part II. Neurol Neuroimmunol Neuroinflamm. 2016;3:e277.
   PubMedGoogle Scholar
• Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler J. 2012;18:5–10.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio EM, La Cava M, Tortorella P, et al. Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis. Semin Ophthalmol. 2017;32:689–701.
   PubMed Web of Science ®Google Scholar
• Bruscolini A, Abbouda A, Locuratolo N, et al. Dry eye syndrome in non-exophthalmic Graves’ Disease. Semin Ophthalmol. 2015;30:372–376.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92:663–679.
   PubMed Web of Science ®Google Scholar
• Trebbastoni A, D’Antonio F, Bruscolini A, et al. Retinal nerve fibre layer thickness changes in Alzheimer’s disease: results from a 12-month prospective case series. Neurosci Lett. 2016;629:165–170.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012;18:1480–1483.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasmaexchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis Optica Study Group. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016 Feb;79(2):206–216.
   PubMed Web of Science ®Google Scholar